Ami specialises in three areas of research: 

His methodological skills in epidemiology, biostatistics, public health and cardiovascular medicine has led to collaborations across traditional disciplines. Since 2006, he has collaborated with Thomas Pogge, a moral philosopher at Yale University and Aidan Hollis, a health economist, at the University of Calgary, to develop and test the Health Impact Fund, a new proposal for incentivising and rewarding pharmaceutical companies in order to improve global access to innovative medicines. Briefly, the Health Impact Fund would be underwritten by governments and would reward companies based on the global health impact of their products. As a co-investigator in a project grant from the European Research Council, Ami is testing the feasibility of health impact assessment of new drugs using big data. 

Although cardiovascular disease is Ami's area of expertise, he is interested in approaches which can be used across diseases in research and clinical practice. He is currently considering adherence to simple drugs (e.g. aspirin, beta-blockers, anti-hypertensives and statins) in acute cardiovascular disease in order to understand the scale of non-adherence in the UK. These data will improve the modelling and calculation of the “real world” impact of drugs in UK clinical practice.  

(iii) Crossing countries   

Non-communicable diseases, especially cardiovascular disease, pose a threat in the UK and globally. As a member of the World Heart Federation’s (WHF) Emerging Leaders Programme, Ami is part of an ambitious network of 25 early-career cardiovascular researchers who are contributing to the WHF’s aim of reducing premature global cardiovascular mortality by 25% by 2025 (the “25 by 25” initiative). As an expert advisor to the Global Burden of Disease Study, he is also involved in global CVD surveillance which will inform future health policy.